IBB News Alert Nasdaq Biotechnology Ishares (IBB) 295.25 11/18/2014

New Post Public Reply Private Reply Replies (0) Message Board

Nov 18, 2014 at 10:14 PM

Nasdaq Biotechnology Ishares (IBB) 295.25 $IBB

Biotech Weekly: Here Come The Institutional Holdings Updates
Daniel Ward - at Seeking Alpha - Mon Nov 17, 7:31AM CST

LOXO: 11.50 (+0.05), TRGT: 2.44 (+0.01), BOTA: 2.25 (+0.01), XBI: 171.38 (+3.00), IBB: 295.25 (+6.41), BIOS: 5.85 (+0.07), RGDO: 0.86 (+0.01), EXEL: 1.74 (-0.02), AMPH: 10.37 (+0.05)

Future Tech: Berkeley Biolabs CEO on Biotech Investments Not to Miss
at The Street - Sat Nov 15, 6:00AM CST
Ryan Bethencourt of Berkeley Biolabs and Indie.Bio, explains why savvy investors need to pay attention to the latest prototypes coming down the biotech pipeline.
XBI: 171.38 (+3.00), IBB: 295.25 (+6.41)

'Fast Money' Recap: Was Friday the Start of a Bull Rally in Gold?
at The Street - Sat Nov 15, 4:00AM CST
The trading panel took a look at gold prices, which climbed 2.3% on Friday, as well as the potential for a pullback in biotech stocks.
AMZN: 324.93 (+1.88), TSRO: 31.45 (+1.46), XBI: 171.38 (+3.00), IBB: 295.25 (+6.41), CELG: 106.78 (+2.42), GILD: 103.71 (+3.27), GLD: 115.05 (+1.00), MCD: 96.41 (+0.44), SLV: 15.55 (+0.05), GDX: 20.30 (+0.91), TWTR: 40.61 (+0.14), AAPL: 115.47 (+1.48), BABA: 110.81 (-3.44)

iShares Nasdaq Biotechnology Index Set to Possibly Rebound After Yesterday's Selloff of 1.96%
Comtex SmarTrend(R) - Fri Nov 14, 3:47PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $286.11 to a high of $294.11. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $292.79 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 295.25 (+6.41)

Look for Shares of iShares Nasdaq Biotechnology Index to Potentially Rebound after Yesterday's 1.96% Sell Off
Comtex SmarTrend(R) - Fri Nov 14, 3:46PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $286.11 to a high of $294.11. Yesterday, the shares fell 2.0%, which took the trading range below the 3-day low of $292.79 on volume of 1.9 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 295.25 (+6.41)

Neothetics on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 12:46PM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41)

S1 Biopharma set for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 12:20PM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41), SXB: ()

Biotech off today led by Biogen
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:00AM CST

BIIB: 305.56 (+3.14), VRTX: 111.04 (-0.58), GILD: 103.71 (+3.27), ALXN: 192.37 (+5.59), AMGN: 162.24 (+3.10), IBB: 295.25 (+6.41), REGN: 413.22 (+13.57), CELG: 106.78 (+2.42)

Cleveland Biolabs; A Diverse Play on Both Biodefense and Cancer
ACCESSWIRE - Thu Nov 13, 9:50AM CST
WHITEFISH, MT / ACCESSWIRE / November 13, 2014 / The biotechnology industry has significantly outperformed the general market for some time now. So far this year, the iShares NASDAQ Biotechnology Index ETF (NASDAQ: IBB) has jumped nearly 30% compared to a nearly 10% return for the S&P 500 SPDR ETF (NYSE: SPY). Investors concerned about the industry's lofty valuation may want to take a look at some smaller diversified players in the space.
SPY: 205.55 (+1.18), AZN: 73.98 (+1.48), IBB: 295.25 (+6.41), CBLI: 0.38 (-0.01)

PRA Health Sciences on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 1:06PM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41), DRGS: 52.96 (+0.96), PRAH: 20.35 (-0.19), IXJ: 101.67 (+1.52), IRY: 48.69 (+0.62)

NeuroDerm on deck for IPO
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 12:38PM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41), NDRM: 8.82 (-0.18)

Biotech Ripe for Correction as Risk of Cyclical Drawdown Looms
at The Street - Mon Nov 10, 2:15PM CST
Look at the performance of the biotechnology sector vs. tech since the 2008 crisis.
XBI: 171.38 (+3.00), XLK: 41.67 (+0.14), IBB: 295.25 (+6.41)

FibroGen on deck for IPO
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 12:46PM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), AZN: 73.98 (+1.48), IBB: 295.25 (+6.41), FGEN: 23.59 (-0.22)

Biotech Weekly: When Mid Caps Are Priced Nearly For Perfection
Daniel Ward - at Seeking Alpha - Mon Nov 10, 9:28AM CST

XBI: 171.38 (+3.00), SLXP: 105.39 (+4.18), ICPT: 162.50 (+4.40), IBB: 295.25 (+6.41), AGIO: 83.81 (-1.07)

Jaguar Animal Health postpones IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 10:57AM CST

IPO: 23.78 (+0.05), JAGX: (), BIS: 50.24 (-2.15), PARN: 4.43 (-0.05), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41)

Joint Corporation on deck for IPO
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 10:46AM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41), JYNT: 6.84 (+0.08)

Nevro debuts strongly
Seeking Alpha - at Seeking Alpha - Fri Nov 07, 10:03AM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41), NVRO: 26.66 (-1.16)

Coherus Bio stumbles in debut
Seeking Alpha - at Seeking Alpha - Thu Nov 06, 12:59PM CST

IPO: 23.78 (+0.05), BIS: 50.24 (-2.15), BIB: 119.71 (+4.71), IBB: 295.25 (+6.41), AMGN: 162.24 (+3.10), CHRS: 13.16 (+0.01)

iShares Nasdaq Biotechnology Index Falls 1.64% on Heavy Volume: Watch For Potential Rebound
Comtex SmarTrend(R) - Wed Nov 05, 4:02PM CST
iShares Nasdaq Biotechnology Index (AMEX:IBB) traded in a range yesterday that spanned from a low of $287.71 to a high of $296.42. Yesterday, the shares fell 1.6%, which took the trading range below the 3-day low of $291.60 on volume of 1.4 million shares. Often times after large one-day declines, short-term traders may play for some degree of mean reversion.
IBB: 295.25 (+6.41)

Newer

Older

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Political Jitters Push US Investors to Golden Visas

Judging by the latest buzz from La Vida's 2026 survey, the golden ticket for many US investors isn't a hot stock but something far more unexpected: the coveted 'Golden Visa.' Out of over 5,000 wealthy individuals invited to participate, 94.3% are mulling over a second residency or citizenship, and the big trigger? Political concerns. It's a clear sign that plenty of...

MTB Auction Spotlights 61 Lots of Key CNC Equipment

A Windfall of Opportunities for Equipment Buyers The hum of CNC machines, the clang of fabrication tools—it's the symphony of progress echoing from workshops around the world. Machine Tool Bids (MTB) is rolling out the red carpet for manufacturing enthusiasts with its October 28 auction. How often do you get a shot at 61 lots of top-tier metalworking equipment at your...

Le Mars Transload Expands: Rail Investment Heats Up

There's a new rail story shaking up the industry—Le Mars, Iowa, is expanding its Transload Center. Look, it's not often a city with just over 10,000 souls makes waves on the logistics scene, but that’s exactly what's happening in Le Mars. This story's got more than just tracks and trains—it's about jobs, economies, and a place proudly dubbed 'The Ice Cream Capital...

Personalis Merger Faces Investigation: $16.25 Offers Scrutinized

Market Storm or Light Drizzle? When the sharks smell blood or the legal eagles start circling, you know something stinks. BFA Law is sniffing around, and it isn’t just for sport. They’re putting their magnifying glass on this curious $16.25 per share transaction where Tempus AI plans to gobble up Personalis lock, stock, and barrel. For investors holding NASDAQ:PSNL,...

CoCo Expands Bubble Tea Empire: Hungary to Ukraine

CoCo's Three-Market Strategy Dive into the world of bubbly enthusiasm: CoCo Bubble Tea is making a splash in Central and Eastern Europe, targeting Hungary, Armenia, and gearing up for Ukraine. No small feat, this move taps straight into the heart of younger consumers who can't get enough of quirky, customizable Asian-inspired drinks. We're not only talking tea—this is a...

Mountain Home Drainage: Tips to Avoid Costly Repairs

Water in the Mountains: A Persistent Challenge Ever try building in the mountains? It's not just about scenic views and fresh air—it's a cunning dance with nature, particularly when it comes to water. The latest scoop from HelloNation underscores the headache that is drainage management in those rugged terrains, featuring insights from construction whiz Jim Weese of...

New Navy Contract Boosts X-Bow's Defense Portfolio

Will X-Bow's CHAOS contract shake up defense? Ever get the feeling you're watching a scrappy upstart quietly transform an industry? That's the buzz around X-Bow Systems Inc (X-Bow®) as they announce a partnership with CoAspire for the U.S. Navy's CHAOS program. This ain't just another contract; it's a cornerstone moment for them. So, what's fueling the excitement?...

XCMG Lends Heavy Equipment to Nairobi Rescue Effort

When Buildings Fall and Heavy Equipment Matters Buildings aren't supposed to just topple over. It's not some new trend I missed, but when it does happen, you've got a crisis – and that's exactly what unfolded in Nairobi on October 23 when an 18-story tower gave out, crashing down into chaos in the Eastleigh neighborhood. From Ground Zero to Immediate Response Imagine...

Lectric eBikes Unveils XP Lite3 with Major Upgrades

Packing Features Without the Price Hike Alright folks, Lectric eBikes just dropped the XP Lite3 onto the scene and, believe me, the air's buzzing. You know how they say the third time's a charm? Well, it sure as heck applies here. Instead of jacking up the price, they're holding on to that $799 sticker like a stubborn mule in a rising-tide economy. And let's chew on that...

M&A Source's 2026 Conference Tackles Deal-Making Drama

High Stakes and Deep Insights Await in Houston Cracking the nut of lower-middle market transactions ain’t a walk in the park. M&A Source®'s Fall 2026 Conference is gearing up to address the very dramas that lurk behind the scenes. Kicking off November 2-4 at the opulent JW Marriott in Houston, Texas, the event is looking to assemble a heavyweight lineup of...